Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,520 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Treatment Given Clear all
Completed Phase 1 Interventional

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Other · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 3 Interventional

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

NCT04229004
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Drug
Lead sponsor
Pancreatic Cancer Action Network
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

NCT05013255
View directory record Official record
Conditions
Breast Cancer, Muscle Fatigue
Interventions
Pioglitazone 15mg, Pioglitazone 30 mg
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Not applicable Interventional

USC and Bodyport Remote Heart Failure Management Study

NCT04975633
View directory record Official record
Conditions
Heart Failure
Interventions
Bodyport Cardiac Scale
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT01691898
View directory record Official record
Conditions
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions
Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 5, 2026, 2:29 PM EDT
Completed No phase listed Observational

The Effect of Midazolam Sedation on Diagnostic Medial Branch Blocks

NCT04453449
View directory record Official record
Conditions
Lumbar Spine Spondylosis, Anxiety Generalized
Interventions
Midazolam
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Statin Reminders for Improving Prescribing in Primary Care

NCT06456658
View directory record Official record
Conditions
Cholesterol, Elevated, Clinical Decision Support, Education
Interventions
Interruptive Reminder, Non-interruptive Reminder, No Reminder
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Enhances Human Immune Function and Reduces Illness

NCT01398150
View directory record Official record
Conditions
Healthy Humans
Interventions
Beverage made to look like the cranberry beverage, Beverage made from cranberry compounds
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

NCT03976050
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
HL-085
Drug
Lead sponsor
Shanghai Kechow Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children

NCT00178490
View directory record Official record
Conditions
Hypertension
Interventions
High blood pressure treatment
Drug
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

NCT03015740
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration, Sitravatinib
Other · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 5, 2026, 2:29 PM EDT
Withdrawn Phase 1 Interventional

Vitamin E Supplementation in Burn Patients

NCT01413620
View directory record Official record
Conditions
Burn Injury
Interventions
dl-alpha-tocopheryl acetate
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
6 Months to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

NCT01865617
View directory record Official record
Conditions
CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 5, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

NCT04891289
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine, Oxaliplatin, Dexamethasone, Floxuridine (FUDR), Implanted Medical Device
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Bethesda, Maryland • St Louis, Missouri • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Not applicable Interventional Results available

An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty

NCT02154243
View directory record Official record
Conditions
Orthostatic Hypotension
Interventions
Midodrine, Intravenous fluid bolus
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NCT00455650
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Mecamylamine, Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 4 Interventional Results available

Health Systems Reach Interventions Project

NCT04199117
View directory record Official record
Conditions
Smoking, Cigarette, Smoking Cessation
Interventions
Varenicline, Combination nicotine patch and nicotine mini-lozenge treatment, Monetary incentives for initiating treatment, Automated tailored outreach, Care management, Wisconsin Tobacco Quit Line referral, Primary care provider referral, Untailored outreach, Multiple smoking cessation coaching calls
Drug · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082
View directory record Official record
Conditions
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
381
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT00655850
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Gemcitabine, Avastin
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)

NCT05319860
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 5, 2026, 2:29 PM EDT
Completed No phase listed Observational

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

NCT02568202
View directory record Official record
Conditions
Haemostasis, Congenital Bleeding Disorder, Haemophilia B
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 5, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Moexipril for Primary Biliary Cirrhosis

NCT00588302
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Moexipril
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 5, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional Results available

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00288054
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, docetaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
77
States / cities
Anchorage, Alaska • Los Angeles, California • Marysville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 5, 2026, 2:29 PM EDT